IN THE NEWS

October 13, 2008
PRNewswire-FirstCall via COMTEX News Network

BOTHELL, Wash., -- Cardiac Science Corporation announced today that it has initiated a worldwide voluntary field corrective action of certain automated external defibrillators (AEDs) manufactured between August 2006 and March 2007. Some AEDs manufactured in this time frame may have a component whose performance doesn't match the factory software settings. Under a particular set of conditions, the software places the AED into a "Service Required" mode.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH510LOGO)

To remedy this and complete the corrective action, Cardiac Science is providing a user-installable software update to affected customers and distributors.

"This voluntary field action is an opportunity for Cardiac Science to demonstrate that we stand behind every one of our products," said John Hinson, chief executive officer.

Cardiac Science has begun notifying distributors and customers with affected devices and is shipping software updates to each. The instructions and additional information regarding the affected units are also available at http://www.cardiacscience.com/AEDUpdate. Customers can also call 1.877.502.2673 or e-mail aedqs99@cardiacsience.com.

Until the updates arrive, customers should keep their AEDs in service. This issue is typically identified in daily self-test, however, there is a remote possibility of occurrence while attempting to provide defibrillation. The Company has received two complaints related to this issue during use.

The company expects to take a pre-tax charge of between $0.8 million and $1.0 million in the third quarter of 2008 relating to the estimated costs associated with this voluntary action. This action will not affect the company's AED manufacturing, shipping schedules, or service support to current or new customers.

"While this unanticipated charge will obviously have an impact on third quarter earnings, we presently expect that we will still finish the full year within the range of our earlier guidance, though we are now more comfortable with the lower end of that range," said Mike Matysik, chief financial officer. Cardiac Science expects to announce its third quarter 2008 results in late October and will provide an update on guidance for the balance of the year at that time.

About Cardiac Science

Cardiac Science, a wholly owned subsidiary of Opto Circuits (India) Ltd., develops, manufactures, and markets a family of advanced diagnostic and therapeutic cardiology devices and systems, including automated external defibrillators (AED), electrocardiograph devices (ECG/EKG), cardiac stress treadmill and systems, PC-based diagnostic workstations, Holter monitoring systems, hospital defibrillators, vital signs monitors, cardiac rehabilitation telemetry systems, and cardiology data management systems (informatics) that connect with hospital information (HIS), electronic medical record (EMR), and other information systems. The company sells a variety of related products and consumables and provides a portfolio of training, maintenance, and support services. Cardiac Science, the successor to the cardiac businesses that established the trusted Burdick^®, HeartCentrix^®, Powerheart^®, and Quinton^® brands, is headquartered in Bothell, Washington. With customers in almost 100 countries worldwide, the company has operations in North America, Europe, and Asia. For information, call 425.402.2000 or visit http://www.cardiacscience.com.

For updates and information on worldwide defibrillation and cardiac monitoring, find us on Facebook at http://facebook.com/cardiacscience, the Cardiac Science blog at http://www.cardiacscience.com/blog, Twitter at http://twitter.com/cardiacscience, and YouTube at http://budurl.com/CSonYT

For information, contact (media) Anastasia Mironova amironova@cardiacscience.com+1.425.402.2092 | (investors) ir@optoindia.com | +91.80.2852.8088 LOGO: http://www.cardiacscience.com/images/main_logo.gif